Precancerous Bile Duct Pathology in End-stage Primary Sclerosing Cholangitis, With and Without Cholangiocarcinoma
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Patients with primary sclerosing cholangitis (PSC) are at increased risk for developing cholangiocarcinoma (CCA). However, the morphology of precursor lesions and the prevalence of biliary dysplasia among patients undergoing liver transplantation for PSC are incompletely defined, and the earlier studies using relatively small number of cases have yielded conflicting results. We retrospectively evaluated 100 consecutive formalin-fixed PSC liver explants (including 30 with CCA) by randomly sampling the hilar and large intrahepatic bile ducts (10 additional tissue cassettes submitted per case). The following histologic features were evaluated and quantitated according to the number of ducts involved: mucinous metaplasia, pyloric metaplasia, intestinal metaplasia, pancreatic acinar metaplasia, and biliary dysplasia [low-grade vs. high-grade (biliary intraepithelial neoplasia-2 or neoplasia-3), papillary vs. flat]. Using Fisher exact test and t test, these features were correlated with the presence or absence of CCA and with the following clinical parameters: sex, age, PSC duration, cirrhotic-stage liver disease, and inflammatory bowel disease at the time of transplant. We found high frequencies of mucinous metaplasia (77%), pyloric metaplasia (73%), and pancreatic acinar metaplasia (10%), which did not differ between CCA and non-CCA livers. However, livers with CCA were more likely to harbor intestinal metaplasia (43% vs. 19%, P=0.013), dysplasia (of any grade) (83% vs. 36%, P<0.0001), and high-grade dysplasia (60% vs. 11%, P<0.0001), and also contained greater numbers of dysplastic ducts than non-CCA cases (P<0.0001). The relative frequency of papillary (44%) versus flat (56%) dysplasia did not differ between CCA and non-CCA cases. Overall, intestinal metaplasia was a significant predictor of bile duct dysplasia (P=0.0005) and CCA (P=0.013), low-grade dysplasia predicted high-grade dysplasia (P<0.0001) and CCA (P=0.0004), and high-grade dysplasia predicted CCA (P<0.0001). Among the clinical parameters, there were no significant differences in age, sex, history of inflammatory bowel disease, or PSC duration, but patients transplanted for CCA were less likely to have cirrhosis (60% vs. 86%, P=0.008). These data strongly support a metaplasia-low-grade dysplasia-high-grade dysplasia-carcinoma sequence in PSC-associated CCA, and underscore the known lack of relationship between patient age and PSC duration in the development of CCA. Even in the absence of CCA, bile duct dysplasia is still a relatively frequent finding, seen at least focally in 36% of benign end-stage PSC explants. Dysplasia, however, is generally confined to large and septal-size bile ducts and its presence may not be recognized unless multiple sections specifically targeted to the biliary tree are examined.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, about one-third of patients with biliary dysplasia have been reported not to have CCA on follow-up and the time interval for progression from dysplasia to carcinoma is unpredictable.342”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [342]
In the citing paper
“Biliary dysplasia of any grade has been reported in 83% of explant livers with PSC-CCA, compared with 36% of those without CCA and the dysplastic changes are often multifocal.342”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [342]
Citations
Cites
Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis
Burak, K., Angulo, P., Pasha, T. M., Egan, K., Petz, J., & Lindor, K. D. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04067.x · Cited by 557 · cited 2×
“With the advent of better imaging techniques and the documentation of PSC for years before the development of CCA, it is now widely accepted that PSC is a major risk factor for CCA, which develops in 7% to 30% of these patients.(4,7,18,21,27) Recent work has suggested that biliary carcinogenesis in PSC arises through…”
BackgroundMethodTischendorf, J. J. W., Hecker, H., Krüger, M., Manns, M. P., & Meier, P. N. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00872.x · Cited by 413 · cited 1×
“With the advent of better imaging techniques and the documentation of PSC for years before the development of CCA, it is now widely accepted that PSC is a major risk factor for CCA, which develops in 7% to 30% of these patients.(4,7,18,21,27) Recent work has suggested that biliary carcinogenesis in PSC arises through…”
MethodCholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study
Chalasani, N., Baluyut, A., Ismail, A., Zaman, A., Sood, G., Ghalib, R., McCashland, T. M., Reddy, R. K., Zervos, X., Anbari, M. A., et al. (2000) · Hepatology · doi:10.1002/hep.510310103 · Cited by 336 · cited 1×
“CCA risk also does not seem to correlate with clinical indices of PSC severity.(8) Similarly, we did not observe any relationship between the degree of bile duct inflammation and the presence or absence of metaplastic or dysplastic epithelium.”
BackgroundLudwig, J., Barham, S. S., Larusso, N. F., Elveback, L. R., Wiesner, R. H., & McCall, J. T. (1981) · Hepatology · doi:10.1002/hep.1840010612 · Cited by 328
The natural history of small-duct primary sclerosing cholangitis
Björnsson, E., Olsson, R., Bergquist, A., Lindgren, S., Braden, B., Chapman, R. W., Boberg, K. M., & Angulo, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.042 · Cited by 305 · cited 1×
“With the advent of better imaging techniques and the documentation of PSC for years before the development of CCA, it is now widely accepted that PSC is a major risk factor for CCA, which develops in 7% to 30% of these patients.(4,7,18,21,27) Recent work has suggested that biliary carcinogenesis in PSC arises through…”
MethodZen, Y., Adsay, N. V., Bardadin, K., Colombari, R., Ferrell, L., Haga, H., Hong, S.-M., Hytiroglou, P., Klöppel, G., Lauwers, G. Y., et al. (2007) · Modern Pathology · doi:10.1038/modpathol.3800788 · Cited by 292 · cited 1×
“In addition to classification of bile ducts as metaplastic, low-grade dysplasia, or high-grade dysplasia, biliary alterations were also classified according to the recently-described nomenclature for biliary intraepithlelial neoplasia (BilIN) grades 1, 2, and 3.(31) Briefly, BilIN-1 included ducts with mucinous metapl…”
MethodBergquist, A., Glaumann, H., Persson, B., & Broomé, U. (1998) · Hepatology · doi:10.1002/hep.510270201 · Cited by 281 · cited 1×
“It has been observed that one-third to one-half of PSC-associated CCAs are found within the first year of the patients’ PSC diagnosis,(20) and thus the mean duration of PSC in CCA cases is either the same or slightly lower than non-CCA cases.(2,7) CCA risk also does not seem to correlate with clinical indices of PSC s…”
BackgroundWee, A., Ludwig, J., Coffey, R. J., LaRusso, N. F., & Wiesner, R. H. (1985) · Human Pathology · doi:10.1016/s0046-8177(85)80158-1 · Cited by 191
Lewis, J. T., Talwalkar, J. A., Rosen, C. B., Smyrk, T. C., & Abraham, S. C. (2007) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213435.99492.8a · Cited by 187
Self-citationAnatomic and molecular pathology of intrahepatic cholangiocarcinoma
Nakanuma, Y., Harada, K., Ishikawa, A., Zen, Y., & Sasaki, M. (2003) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s00534-002-0729-3 · Cited by 121 · cited 3×
“Some earlier studies have noted that intrahepatic bile duct dysplasia preferentially involves the large and septal-sized ducts whereas interlobular bile ducts are typically unaffected.(23,28) This finding is observed in both PSC-associated and non-PSC-associated biliary dysplasia, and suggests that sampling of periphe…”
Background
Cited by
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Primary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868
“S e m in a r JOURNAL OF HEPATOLOGY (elevated levels may be observed with cholangitis or other malignancies).207 Genetic variants in the fucosyltransferases 2 and 3 (FUT2/FUT3) influence CA19-9 levels.208 MRI and computerised tomography may visualise early features of CCA in PSC, but difficulties in distinguishing infl…”
BackgroundInfluentialEASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Epidemiology of cholangiocarcinoma
Bergquist, A., & von Seth, E. (2015) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2015.02.003 · Cited by 400
“About one third of patients exhibiting biliary dysplasia will not have CCA on follow-up [56,79].”
Anatomical, histomorphological and molecular classification of cholangiocarcinoma
Kendall, T., Verheij, J., Gaudio, E., Evert, M., Guido, M., Goeppert, B., & Carpino, G. (2019) · Liver International · doi:10.1111/liv.14093 · Cited by 350
Miyazaki, M., Yoshitomi, H., Miyakawa, S., Uesaka, K., Unno, M., Endo, I., Ota, T., Ohtsuka, M., Kinoshita, H., Shimada, K., et al. (2015) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.233 · Cited by 298
“PSC shows no symptoms in its early stage.”
BackgroundCancer surveillance in patients with primary sclerosing cholangitis
Razumilava, N., Gores, G. J., & Lindor, K. D. (2011) · Hepatology · doi:10.1002/hep.24570 · Cited by 292
Chapman, M. H., Webster, G. J. M., Bannoo, S., Johnson, G. J., Wittmann, J., & Pereira, S. P. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283554bbf · Cited by 204
Hsu, M., Sasaki, M., Igarashi, S., Sato, Y., & Nakanuma, Y. (2013) · Cancer · doi:10.1002/cncr.27955 · Cited by 125
“To our knowledge, there have been no other studies demonstrating KRAS mutations in the background of bile duct and PBG lesions in patients with BilIN and ICC.”
BackgroundInfluentialUpdate on primary sclerosing cholangitis
Karlsen, T. H., & Boberg, K. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.015 · Cited by 122
“, dominant strictures) is controversial since up to 1/3 of PSC patients may show such features [98,104,105].”
BackgroundPrimary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management
Ilyas, S. I., Eaton, J. E., & Gores, G. J. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.05.035 · Cited by 122
“Liver explants from patients with concomitant PSC and CCA are more likely to harbor high-grade dysplasia compared with PSC explants without CCA.(6) Moreover, cytogenetic assessment of liver explants with biliary dysplasia from patients with PSC has demonstrated that patients with previous or current CCA are more likel…”
Fritcher, E. B. G., Kipp, B. R., Voss, J. S., Clayton, A. C., Lindor, K. D., Halling, K. C., & Gores, G. J. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.272 · Cited by 114
Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review
Song, J., Li, Y., Bowlus, C. L., Yang, G., Leung, P. S. C., & Gershwin, M. E. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08764-7 · Cited by 112
Ponsioen, C. Y., Assis, D. N., Boberg, K. M., Bowlus, C. L., Deneau, M., Thorburn, D., Aabakken, L., Färkkilä, M., Petersen, B., Rupp, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.046 · Cited by 95
Karlsen, T. H., Vesterhus, M., & Boberg, K. M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12581 · Cited by 86
Primary sclerosing cholangitis and malignancy
Boberg, K. M., & Lind, G. E. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.10.002 · Cited by 81
Chung, B. K., Karlsen, T. H., & Folseraas, T. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.020 · Cited by 81
“Thus, cholangiocyte dysplasia may serve as a predictor for PSC-CCA, however dysplasia is also relatively frequent in the absence of PSC-CCA and may regress after resolution of biliary tract infections [71,76,77].”
BackgroundBiliary Multifocal Chromosomal Polysomy and Cholangiocarcinoma in Primary Sclerosing Cholangitis
Eaton, J. E., Fritcher, E. G. B., Gores, G. J., Atkinson, E. J., Tabibian, J. H., Topazian, M. D., Gossard, A. A., Halling, K. C., Kipp, B. R., & Lazaridis, K. N. (2015) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.433 · Cited by 67
Cancer Risk and Surveillance in Primary Sclerosing Cholangitis
Folseraas, T., & Boberg, K. M. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.08.014 · Cited by 65
Liver Transplant for Cholangiocarcinoma
Zamora‐Valdés, D., & Heimbach, J. K. (2018) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2018.01.002 · Cited by 61
Nakanuma, Y., Zen, Y., & Portmann, B. C. (2012) · MacSween's Pathology of the Liver · doi:10.1016/b978-0-7020-3398-8.00010-6 · Cited by 56
Marsh, R., Alonzo, M. J., Bajaj, S., Baker, M. S., Elton, E., Farrell, T. A., Gore, R. M., Hall, C. R., Nowak, J. A., Roy, H. K., et al. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23028 · Cited by 54
Vedeld, H. M., Grimsrud, M. M., Andresen, K., Pharo, H. D., von Seth, E., Karlsen, T. H., Honne, H., Paulsen, V., Färkkilä, M. A., Bergquist, A. M., et al. (2021) · Hepatology · doi:10.1002/hep.32125 · Cited by 59
“[13] In patients with CCA, aberrant DNA methylation has been observed in both blood and bile, emphasizing the potential of such markers for early detection of CCA.”
InfluentialImpact on follow‐up strategies in patients with primary sclerosing cholangitis
Bergquist, A. M., Weismüller, T. J., Levy, C., Rupp, C., Joshi, D., Nayagam, J. S., Montaño‐Loza, A. J., Lytvyak, E., Wunsch, E., Milkiewicz, P., et al. (2022) · Liver International · doi:10.1111/liv.15286 · Cited by 52
“728 599 (17) 342 (21) 94 (18) 0 (4) Including ERCP 1897 1118 (75) 381 (55) 107 (27) 0 (1) MRI and/or US 350 260 (31) 172 (24) 89 (17) 0 (10) Clinical follow-up 0 5 10 15 20 Follow-up (years) Scheduled imaging Clinical follow-up”
Histological features of precancerous and early cancerous lesions of biliary tract carcinoma
Aishima, S., Kubo, Y., Tanaka, Y., & Oda, Y. (2014) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.71 · Cited by 53
“suggests that intestinal metaplasia was found in 43% of PSCs with cholangiocarcinoma cases and in 19% of PSCs without cholangiocarcinoma cases [18].”
BackgroundAndersen, I. M., Fosby, B., Boberg, K. M., Clausen, O. P. F., Jebsen, P., Melum, E., Line, P. D., Foss, A., Schrumpf, E., & Karlsen, T. H. (2015) · Transplantation Direct · doi:10.1097/txd.0000000000000548 · Cited by 45
“A strong relationship between bile duct dysplasia and the presence of cholangiocarcinoma has been suggested.(17) In this study, no relationship between disease stage and dysplasia was observed, showing that prognostic models for cirrhosis development in PSC have little relevance in forecasting malignancies.”
BackgroundPreneoplastic lesions in the liver: Molecular insights and relevance for clinical practice
Desjonqueres, E., Campani, C., Marra, F., Zucman‐Rossi, J., & Nault, J. (2022) · Liver International · doi:10.1111/liv.15152 · Cited by 50
Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat
Bonato, G., Cristoferi, L., Strazzabosco, M., & Fabris, L. (2015) · Digestive Diseases · doi:10.1159/000440826 · Cited by 39
Tenca, A., Mustonen, H., Lind, K., Lantto, E., Kolho, K., Boyd, S., Arola, J., Jokelainen, K., & Färkkilä, M. (2018) · Liver International · doi:10.1111/liv.13899 · Cited by 37
Sasaki, M., Nitta, T., Sato, Y., & Nakanuma, Y. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.09.016 · Cited by 36
Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk
Navaneethan, U. (2014) · Gastroenterology report · doi:10.1093/gastro/gou036 · Cited by 36
“Even in the absence of cancer, bile duct dysplasia was seen, at least focally, in 36% of benign end-stage PSC explants [90].”
BackgroundKinoshita, M., Kubo, S., Nakanuma, Y., Sato, Y., Takemura, S., Tanaka, S., Hamano, G., Ito, T., Terajima, H., Yamada, T., et al. (2015) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.305 · Cited by 34
“reported that BilIN-2/3 lesions were observed in 50% of patients with end-stage PSC who underwent liver transplantation [15].”
BackgroundTwo distinct pathways of carcinogenesis in primary sclerosing cholangitis: Cholangiocarcinoma in PSC
Zen, Y., Quaglia, A., Heaton, N. D., Rela, M., & Portmann, B. C. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.04048.x · Cited by 34
“Lewis et al.(6) reported recently that intestinal metaplasia was found in 43% of PSC patients with cholangiocarcinoma, and suggested the possible involvement of a metaplasia–dysplasia–carcinoma sequence in PSC.”
BackgroundKerr, S. E., Fritcher, E. G. B., Campion, M. B., Voss, J. S., Kipp, B. R., Halling, K. C., & Lewis, J. T. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.05.008 · Cited by 33
“After approval from the Mayo Clinic Institutional Review Board, 17 liver explants from patients with PSC in which biliary dysplasia had been previously identified by an extensive sectioning protocol [7] during the years 2000 to 2005 were selected for study.”
BackgroundMethodSelf-citationHepatobiliary disorders and complications of inflammatory bowel disease
Venkatesh, P. G. K., Navaneethan, U., & Shen, B. (2011) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2011.00511.x · Cited by 37
Catanzaro, E., Gringeri, E., Burra, P., & Gambato, M. (2023) · Cancers · doi:10.3390/cancers15204947 · Cited by 34
“This observation could explain the different epidemiology PSC-CCA compared with de novo CCA and the earlier development of PSC-CCA [53].”
BackgroundResultBoyd, S., Mustonen, H. K., Tenca, A., Jokelainen, K., Arola, J., & Färkkilä, M. A. (2016) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2016.1250281 · Cited by 34
“mas, CCA is thought to develop through metaplasia, low-grade dysplasia and high-grade dysplasia.[6] CCA generally presents as a contraindication for liver transplantation (LT) and carries a dismal prognosis.”
BackgroundAn update on cholangiocarcinoma associated with primary sclerosing cholangitis
Fevery, J., & Verslype, C. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328337b311 · Cited by 28
Monitoring dominant strictures in primary sclerosing cholangitis with brush cytology and FDG-PET
Sangfelt, P., Sundin, A., Wanders, A., Rasmussen, I. C., Karlson, B., Bergquist, A. M., & Rorsman, F. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.032 · Cited by 26
“The concept of serial brushing of bile ducts in PSC is based on the evidence of a stepwise progression from normal to dysplastic and cancerous epithelium [5–7].”
BackgroundGenetic and Epigenetic Abnormalities in Primary Sclerosing Cholangitis-associated Cholangiocarcinoma
Timmer, M. R., Beuers, U. H., Fockens, P., Ponsioen, C. Y., Rauws, E. A., Wang, K. K., & Krishnadath, K. K. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318281f49a · Cited by 25
“In PSC, the strong association between biliary dysplasia and malignancy suggests that the development of PSC-associated CCA is a multistep process following the inflammation–dysplasia–carcinoma sequence.(23,24) In addition to the potential toxic effect of bile acids on susceptible cholangiocytes in PSC, the release of…”
BackgroundSandanayake, N. S., Camuzeaux, S., Sinclair, J., Blyuss, O. B., Andreola, F., Chapman, M. H., Webster, G. J. M., Smith, R. C., Timms, J. F., & Pereira, S. P. (2014) · BMC Clinical Pathology · doi:10.1186/1472-6890-14-7 · Cited by 24
“Despite this, the profiling failed to accurately differentiate patients with BTC versus the small subset of patients with PSC – a risk factor for BTC [30].”
ResultZenouzi, R., Weismüller, T. J., Jørgensen, K. K., Bubenheim, M., Lenzen, H., Huebener, P., Schulze, K., Weiler‐Normann, C., Sebode, M., Ehlken, H., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.07.032 · Cited by 27
“In this study, subepithelial chronic inflammation was present mainly in bile ducts with pyloric metaplasia.(20) Recent investigations on this issue performed with fluorescence in situ hybridization (FISH) demonstrated cytogenetic abnormalities in dysplastic bile ducts similar to those observed in CCA.”
BackgroundPrecursors to Cholangiocarcinoma
Hucl, T. (2019) · Gastroenterology Research and Practice · doi:10.1155/2019/1389289 · Cited by 23
Primary Sclerosing Cholangitis and Cholangiocarcinoma: Pathogenesis and Modes of Diagnostics
Ehlken, H., & Schramm, C. (2013) · Digestive Diseases · doi:10.1159/000347206 · Cited by 24
Benign biliary neoplasms and biliary tumor precursors
Sarcognato, S., Sacchi, D., Fassan, M., Fabris, L., Cadamuro, M., Zanus, G., Cataldo, I., Covelli, C., Capelli, P., Furlanetto, A., et al. (2021) · Pathologica · doi:10.32074/1591-951x-251 · Cited by 22
Grimsrud, M. M., & Folseraas, T. (2019) · Liver International · doi:10.1111/liv.14180 · Cited by 26
von Seth, E., Ouchterlony, H., Dobra, K., Hjerpe, A., Arnelo, U., Haas, S., & Bergquist, A. M. (2018) · Liver International · doi:10.1111/liv.14007 · Cited by 21
Kamp, E. J. C. A., Dinjens, W. N. M., Doukas, M., van Marion, R., Verheij, J., Ponsioen, C. Y., Bruno, M. J., Koerkamp, B. G., Trivedi, P. J., Peppelenbosch, M. P., et al. (2022) · The Journal of Pathology · doi:10.1002/path.5994 · Cited by 24
Villard, C., Jorns, C., & Bergquist, A. M. (2024) · eGastroenterology · doi:10.1136/egastro-2023-100045 · Cited by 21
Boyd, S., Vannas, M. J., Jokelainen, K., Isoniemi, H., Mäkisalo, H., Färkkilä, M. A., & Arola, J. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i33.6147 · Cited by 20
Preneoplastic conditions underlying bile duct cancer
Sibulesky, L., Nguyen, J. H., & Patel, T. C. (2012) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-012-0943-7 · Cited by 18
Primary sclerosing cholangitis
von Seth, E., Karlsen, T. H., Tanaka, A., Ponsioen, C. Y., & Bergquist, A. M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02582-6 · Cited by 17
Zen, Y., Hübscher, S. G., & Nakanuma, Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00009-1 · Cited by 21
Precursor neoplastic lesions of the biliary tract
Serra, S. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202435 · Cited by 16
Vannas, M. J., Boyd, S., Färkkilä, M. A., Arola, J., & Isoniemi, H. (2016) · Liver International · doi:10.1111/liv.13276 · Cited by 16
Bankov, K., Döring, C., Schneider, M., Hartmann, S., Winkelmann, R., Albert, J., Bechstein, W. O., Zeuzem, S., Hansmann, M. L., Peveling‐Oberhag, J., et al. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/s41424-018-0015-6 · Cited by 16
Role of Endoscopy in Primary Sclerosing Cholangitis
Bhat, P., & Aabakken, L. (2020) · Clinical Endoscopy · doi:10.5946/ce.2020.019-iden · Cited by 14
“The dysplasia-carcinoma sequence is so well established in this population that referral for evaluation for transplantation based on dysplastic duct cytology alone prior to the development of CCA should be strongly considered.(18,19) The addition of fluorescence in-situ hybridization (FISH) analysis of the brush mater…”
BackgroundHachiya, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15925 · Cited by 13
Lee, H. H., Rabinovitch, P. S., Mattis, A. N., Kakar, S., & Choi, W. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.04.002 · Cited by 12
“[40] demonstrated that cholangiocarcinoma cases more frequently harbor dysplasia (any grade; 83% versus 36%, respectively, p < 0.”
BackgroundAdvanced cytologic approaches for the diagnosis of pancreatobiliary cancer
Fritcher, E. G. B., & Halling, K. C. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283383bd0 · Cited by 11
Boyd, S., Mustamäki, T., Sjöblom, N., Nordin, A. J., Tenca, A., Jokelainen, K., Rantapero, T., Liuksiala, T., Lahtinen, L., Kuopio, T., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000415 · Cited by 12
“[5] Brush cytology (BC) is generally recommended to identify dysplasia or CCA in patients with PSC. [6] The main precursors of CCA are biliary intraepithelial neoplasia (dysplasia) and intraductal papillary neoplasms of the bile duct.”
BackgroundWalter, D. H., Herrmann, E. M., Winkelmann, R., Albert, J., Liese, J., Schnitzbauer, A. A., Zeuzem, S., Hansmann, M., Peveling‐Oberhag, J., & Hartmann, S. (2016) · Histopathology · doi:10.1111/his.13041 · Cited by 11
“The prognostic relevance of CD15 molecules is still discussed, as high expression of sCD15 could be correlated with poor outcome with various forms of cancer, including CCA.17–19 Furthermore, overexpression of CD15 has been shown to participate in resistance mechanisms to targeted therapy in colon cancer.20 However, t…”
BackgroundInfluentialPrimary sclerosing cholangitis – the Norwegian experience
Schrumpf, E., Boberg, K. M., & Karlsen, T. H. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1028996 · Cited by 11
UEG Week 2019 Poster Presentations
Jaeger, M.-C., Guiraud, L., Rolland-Fourcade, C., Rolland, C., Belot, A., Sebbag, M., Bermúdez‐Humarán, L. G., Langella, P., Vergnolle, N., & Deraison, C. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619854671 · Cited by 12
PSC and colitis: A complex relationship
Horst, L. J., Kempski, J., Walmsley, M., Huber, S., & Schramm, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001236 · Cited by 12
Tejaswi, S., Olson, K., & Loehfelm, T. W. (2021) · VideoGIE · doi:10.1016/j.vgie.2021.01.009 · Cited by 10
“It is vital to examine as much of the hilar region as possible because CCA tends to predominantly affect this region.(8) After examination of the extrahepatic bile duct, a cholangiogram of the intrahepatic biliary tree can be obtained via contrast injected through the accessory channel of the cholangioscope.”
BackgroundTrilianos, P., Selaru, F. M., Li, Z., & Gurakar, A. O. (2014) · Digestion · doi:10.1159/000357445 · Cited by 9
Liu, Y.-J., & Yeh, M. M. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.06.012 · Cited by 10
Dysplasia and Early Carcinoma of the Gallbladder and Bile Ducts
Adsay, V. N., & Baştürk, O. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.10.001 · Cited by 13
Akbarzadeh, L., Geramizadeh, B., Kazemi, K., Nikeghbalian, S., & Malek‐Hosseini, S. A. (2016) · Hepatitis Monthly · doi:10.5812/hepatmon.38726 · Cited by 9
“worked on explanted livers and took more sections especially from large bile ducts (4); but other studies used needle biopsy or if they worked on whole livers, they had limited number of sections (8, 17, 18).”
BackgroundResultInfluentialAttauabi, M., Wewer, M. D., Bendtsen, F., Seidelin, J. B., & Burisch, J. M. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac003 · Cited by 9
Cancer risk, screening and surveillance in primary sclerosing cholangitis
Chascsa, D. M. H., & Lindor, K. D. (2019) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.19.02586-8 · Cited by 12
Intestinal phenotypes in pediatric gallbladder epithelium
Zen, Y., Zen, C., Quaglia, A., Davenport, M., Heaton, N. D., & Portmann, B. C. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.12.012 · Cited by 7
Novel diagnostic and prognostic biomarkers in biliary tract cancer
Skipworth, J. R. A., Timms, J. F., & Pereira, S. P. (2013) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2013.826646 · Cited by 8
Lee, S., Kim, J. H., Lee, J. H., Zen, Y., & Han, J. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-14218-x · Cited by 7
Matsche, M., Blazer, V., Pulster, E. L., & Mazik, P. M. (2020) · Diseases of Aquatic Organisms · doi:10.3354/dao03510 · Cited by 7
von Meyenburg complexes are more frequently associated with cholangiocarcinoma
Jain, D., Khandakar, B., Ni, P., Kenney, B. C., Qin, L., Deshpande, V., & Fiel, M. I. (2024) · Journal of Clinical Pathology · doi:10.1136/jcp-2024-209572 · Cited by 6
“…leading to increased epithelial turn-over, eventually leading to preneoplasia (biliary intraepithelial neoplasia Bil-IN) and neoplasia, that is, CC. 26 27 It is also clear that epithelial neoplasms at different sites can arise from either flat epithelial lesions (dysplasia/carcinoma in situ) or…”
BackgroundQuigley, B., & Adsay, V. N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00010-8 · Cited by 9
Squamous cell carcinoma of the common bile duct: A case report with genomic profiling
Nguyen, K., Mortensen, M. B., & Detlefsen, S. (2019) · Pathology International · doi:10.1111/pin.12806 · Cited by 4
Cholangiocarcinoma – new concepts and classifications
Wyatt, J. I. (2011) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2011.10.005 · Cited by 4
Advances in Hepatobiliary Pathology: Update for 2010
Lefkowitch, J. H. (2010) · Clinics in Liver Disease · doi:10.1016/j.cld.2010.07.007 · Cited by 4
Biliary intraepithelial neoplasia: a case with benign biliary stricture
Jung, W., & Kim, B. (2011) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2011.17.4.328 · Cited by 4
Jain, D., & Nayak, N. C. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200472 · Cited by 4
Díaz‐González, Á., Molera, C., Gómez-Domínguez, E., Muñoz‐Bartolo, G., Ampuero, J., Fernández‐Rodríguez, C., Quintero, J., Molina, E., Salcedo, M., Olveira, A., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502629 · Cited by 3
Unique clinical, morphological, and molecular characteristics of tumors associated with PSC-IBD
Vajsová, A., Cahová, M., Bajer, L., Sticová, E., Jusková, I., Hlavatý, M., & Fabián, O. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04072-y · Cited by 3
“This may drive cholangiocytes to proliferation, undergoing various metaplastic changes and subsequent development of dysplasia [49].”
Montalvo-Jave, E. E., Chablé-Montero, F., Toapanta-Yanchapaxi, L. N., Rojas-Mendoza, F., López-Caballero, C., Roca-Cabrera, M. L., & Barrera, G. E. M. (2015) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31285-2 · Cited by 3
Tenca, A., Kolho, K., Consonni, D., Jokelainen, K., & Färkkilä, M. A. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12583 · Cited by 3
Zarei, M., Shasaeefar, A., Kazemi, K., Dehghani, M., Malek‐Hosseini, S. A., & Geramizadeh, B. (2019) · Clinical Pathology · doi:10.1177/2632010x19876934 · Cited by 3
Desmet, V. J., & Rosaí, J. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06969-4.00001-5 · Cited by 4
Epithelial precursor lesions of the bile duct
Zheng, W., & Xue, Y. (2025) · Seminars in Diagnostic Pathology · doi:10.1016/j.semdp.2025.150961 · Cited by 2
Wu, B., Liu, Y.-J., Rogers, J. D., Liu, Y., Rabinovitch, P. S., Small, T., Swanson, P. E., & Yeh, M. M. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab130 · Cited by 2
Koistinen, H. K., Boyd, S., Arola, J., Jokelainen, K., Koistinen, R., Lempiäinen, A., Hotakainen, K., Stenman, U., & Färkkilä, M. A. (2021) · Livers · doi:10.3390/livers1040025 · Cited by 2
“CCA is preceded by biliary dysplasia, which is a highly significant predictor of later development of CCA [3].”
BackgroundZen, Y., Hübscher, S. G., & Nakanuma, Y. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00009-0 · Cited by 3
Matsche, M., Blazer, V., & Pulster, E. L. (2023) · Diseases of Aquatic Organisms · doi:10.3354/dao03733 · Cited by 2
Preneoplastic and Neoplastic Biliary Diseases
Liang, T. Z., & Chopra, S. (2025) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000497 · Cited by 2
Baştürk, O., & Adsay, V. N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00010-7 · Cited by 3
Breder, S., Villard, C., Eide, E., Wang, B., Engesæter, L. K., Reims, H. M., Hov, J. R., Melum, E., Aabakken, L., Line, P., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101598 · Cited by 2
“This is supported by previous studies identifying HGD as a stronger predictor than LGD for the presence of CCA 7,29 and by our data showing that HGD or CCA was confirmed in nearly 50% of explant livers from individuals listed for transplantation due to HGD. Ultimately, an individualized assessment…”
Vedeld, H. M., Breder, S., Pharo, H. D., Brodal, H. P., Adolfsen, E. M., Brandt‐Winge, S., von Seth, E., Grimsrud, M. M., Yaqub, S., Karlsen, T. H., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101876 · Cited by 1
“14,15 In PSC, CCA may develop through a dysplasia-carcinoma sequence, 16 suggesting that surveillance for early CCA detection is feasible.”
Single-Stitch Telescopic Bilioenterostomy in an Animal Model
Vrochides, D. V., Νtinas, A., Kardassis, D., Miliaras, D., Metrakos, P. P., & Papalois, A. E. (2012) · Journal of Investigative Surgery · doi:10.3109/08941939.2011.652729 · Cited by 1
“cancer [21, 22]; a similar role in adenocarcinoma formation has been postulated for intestinal metaplasia of the biliary epithelium [23, 24].”
BackgroundZimmermann, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-26587-2_28-1 · Cited by 1
Metadata
- Authors
- Lewis, J. T., Talwalkar, J. A., Rosen, C. B., Smyrk, T. C., & Abraham, S. C.
- Affiliations
- DeKalb Medical Center (US)
- Mayo Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Lewis, Jason T.
- Venue
- American Journal of Surgical Pathology
- Published
- 2010-01
- Volume
- 34
- Issue
- 1
- Pages
- 27-34
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W1985358323
- Cited by
- 122
- References
- 31
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 8 · 2020: 5 · 2019: 8 · 2018: 5 · 2017: 8 · 2016: 12 · 2015: 10 · 2014: 11 · 2013: 6 · 2012: 4
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Surgical Pathology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- primary sclerosing cholangitis, cholangiocarcinoma, biliary dysplasia, biliary intraepithelial neoplasia, intestinal metaplasia, mucinous metaplasia, pyloric metaplasia, liver transplantation, liver explants, inflammatory bowel disease, cholangiocarcinoma risk
- MeSH terms
- Adolescent, Adult, Aged, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Female, Humans, Male, Metaplasia, Middle Aged, Precancerous Conditions, Retrospective Studies, Cholangitis, Sclerosing, Cholangiocarcinoma, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.